Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

[1]  Nicholas D. Adams,et al.  Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. , 2019, Cancer cell.

[2]  U. Ghoshdastider,et al.  Proteomics profiling of arginine methylation defines PRMT5 substrate specificity , 2019, Science Signaling.

[3]  Xiaobing Shi,et al.  PRMT1 loss sensitizes cells to PRMT5 inhibition , 2019, Nucleic acids research.

[4]  A. Krainer,et al.  Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. , 2019, Cancer cell.

[5]  G. Pavesi,et al.  hmSEEKER: Identification of hmSILAC Doublets in MaxQuant Output Data , 2019, Proteomics.

[6]  A. Gavin,et al.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.

[7]  R. Verdun,et al.  PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. , 2018, Cell reports.

[8]  Steven J. M. Jones,et al.  Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients , 2018, Cancer cell.

[9]  Diego Garrido-Martín,et al.  ggsashimi: Sashimi plot revised for browser- and annotation-independent splicing visualization , 2018, PLoS Comput. Biol..

[10]  B. Ebert,et al.  Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. , 2018, Cancer cell.

[11]  C. Holt,et al.  FUS Phase Separation Is Modulated by a Molecular Chaperone and Methylation of Arginine Cation-π Interactions , 2018, Cell.

[12]  M. Simons,et al.  Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation , 2018, Cell.

[13]  J. Teruya-Feldstein,et al.  Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs , 2018, Stem cell reports.

[14]  M. Warmuth,et al.  H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers , 2018, Nature Medicine.

[15]  Thawfeek M. Varusai,et al.  The Reactome Pathway Knowledgebase , 2017, Nucleic Acids Res..

[16]  P. Sharp,et al.  Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. , 2017, Cancer cell.

[17]  Margaret A. Goralski,et al.  Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15 , 2017, Science.

[18]  T. Owa,et al.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides. , 2017, Nature chemical biology.

[19]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[20]  Michael G. Kharas,et al.  Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. , 2017, Cell stem cell.

[21]  S. M. Lewis,et al.  Methylarginines within the RGG-Motif Region of hnRNP A1 Affect Its IRES Trans-Acting Factor Activity and Are Required for hnRNP A1 Stress Granule Localization and Formation. , 2017, Journal of molecular biology.

[22]  R. Fulton,et al.  Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome , 2017, Nature Communications.

[23]  Michelle C. Chen,et al.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. , 2016, Cancer cell.

[24]  Lucas C. Reineke,et al.  Arginine Demethylation of G3BP1 Promotes Stress Granule Assembly* , 2016, The Journal of Biological Chemistry.

[25]  S. Aerts,et al.  p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity , 2016, Nature Medicine.

[26]  Eunhee Kim,et al.  RNA splicing factors as oncoproteins and tumour suppressors , 2016, Nature Reviews Cancer.

[27]  A. Kernytsky,et al.  MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. , 2016, Cell reports.

[28]  S. Armstrong,et al.  Modulation of splicing catalysis for therapeutic targeting of leukemias with spliceosomal mutations , 2016, Nature Medicine.

[29]  Kyle V. Butler,et al.  A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. , 2016, ACS chemical biology.

[30]  T. Golub,et al.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells , 2016, Science.

[31]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[32]  Robert A Copeland,et al.  Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. , 2016, ACS medicinal chemistry letters.

[33]  C. Leslie,et al.  Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing , 2015, eLife.

[34]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2015, Nucleic Acids Res..

[35]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[36]  Alexander V Penson,et al.  Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities , 2015, Proceedings of the National Academy of Sciences.

[37]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[38]  F. Boisvert,et al.  Author response: Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes , 2015 .

[39]  H. Deeg,et al.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.

[40]  C. Koh,et al.  MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis , 2015, Nature.

[41]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[42]  J. Delrow,et al.  Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells , 2015, Nature Biotechnology.

[43]  Stuart A. Wilson,et al.  Arginine methylation and citrullination of splicing factor proline- and glutamine-rich (SFPQ/PSF) regulates its association with mRNA , 2015, RNA.

[44]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[45]  Lan Lin,et al.  rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data , 2014, Proceedings of the National Academy of Sciences.

[46]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[47]  Guanming Wu,et al.  ReactomeFIViz : a Cytoscape app for pathway and network-based data analysis , 2022 .

[48]  Paul Theodor Pyl,et al.  HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[49]  J. Valcárcel,et al.  Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.

[50]  Jian Zhang,et al.  Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.

[51]  Sanjeeb Kumar Sahu,et al.  Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery , 2013, Genes & development.

[52]  M. Wilkins,et al.  Interactions Affected by Arginine Methylation in the Yeast Protein–Protein Interaction Network* , 2013, Molecular & Cellular Proteomics.

[53]  A. Hinnebusch,et al.  Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 , 2013, Nature Genetics.

[54]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[55]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[56]  S. Richard,et al.  Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs , 2013, Scientific Reports.

[57]  A. Bowcock,et al.  Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma , 2013, Nature Genetics.

[58]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[59]  A. Krainer,et al.  THE SPLICING FACTOR SRSF1 REGULATES APOPTOSIS AND PROLIFERATION TO PROMOTE MAMMARY EPITHELIAL CELL TRANSFORMATION , 2011, Nature Structural &Molecular Biology.

[60]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[61]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[62]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[63]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[64]  Luis Alejandro Rojas,et al.  The C-Terminal Domain of RNA Polymerase II Is Modified by Site-Specific Methylation , 2011, Science.

[65]  R. Reed,et al.  The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. , 2011, Genes & development.

[66]  Qin M. Chen,et al.  Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding , 2010, Nature chemical biology.

[67]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[68]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[69]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[70]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[71]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[72]  M. Jansson,et al.  Arginine methylation regulates the p53 response , 2008, Nature Cell Biology.

[73]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[74]  T. Owa,et al.  Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.

[75]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[76]  G. Merz,et al.  Methylation regulates the intracellular protein-protein and protein-RNA interactions of FMRP , 2006, Journal of Cell Science.

[77]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  M. Mann,et al.  Identifying and quantifying in vivo methylation sites by heavy methyl SILAC , 2004, Nature Methods.

[79]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[80]  Utz Fischer,et al.  Assisted RNP assembly: SMN and PRMT5 complexes cooperate in the formation of spliceosomal UsnRNPs , 2002, The EMBO journal.

[81]  G. Meister,et al.  Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln , 2001, Current Biology.

[82]  Marc Montminy,et al.  A Transcriptional Switch Mediated by Cofactor Methylation , 2001, Science.

[83]  G. Dreyfuss,et al.  SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets. , 2001, Molecular cell.

[84]  X. W. Wang,et al.  The RGG domain in hnRNP A2 affects subcellular localization. , 2000, Experimental cell research.

[85]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[86]  S. Richard,et al.  Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. , 2012, Human molecular genetics.

[87]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[88]  F. Boisvert,et al.  Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. , 2003, Molecular biology of the cell.

[89]  R. Denman.  Methylation of the arginine-glycine-rich region in the fragile X mental retardation protein FMRP differentially affects RNA binding. , 2002, Cellular & molecular biology letters.